Loading...

Gilead Sciences, Inc.

GIS.DEXETRA
Healthcare
Drug Manufacturers - General
117.60
-1.46(-1.23%)
German Market opens in 9h 22m

Gilead Sciences, Inc. (GIS.DE) Stock Competitors & Peer Comparison

See (GIS.DE) competitors and their performances in Stock Market.

Peer Comparison Table: Drug Manufacturers - General Industry

Detailed financial metrics including price, market cap, P/E ratio, and more.

SymbolPriceChange %Market CapP/E RatioEPSDividend Yield
GIS.DE€119.06+1.54%147.8B20.53€5.80+2.30%
LLY.DE€792.90-0.39%749.1B40.31€19.67+0.68%
JNJ.DE€204.10+1.21%491.6B21.58€9.46+2.18%
4AB.DE€176.65+1.44%312.5B87.45€2.02+3.24%
6MK.DE€101.90-0.18%251.9B16.33€6.24+2.79%
ZEG.DE€160.70+0.59%249.2B28.75€5.59+1.69%
AMG.DE€297.05+0.07%160.1B24.31€12.22+2.78%
PFE.F€22.98-0.02%131.5B19.93€1.16+6.36%
PFE.DE€23.12+0.85%131.5B19.93€1.16+6.35%
BRM.DE€49.61+0.40%101B16.76€2.96+4.32%
1

Stock Comparison

Select a stock to compare (requires JavaScript). Showing default comparison.

GIS.DE vs LLY.DE Comparison April 2026

GIS.DE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GIS.DE stands at 147.8B. In comparison, LLY.DE has a market cap of 749.1B. Regarding current trading prices, GIS.DE is priced at €119.06, while LLY.DE trades at €792.90.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GIS.DE currently has a P/E ratio of 20.53, whereas LLY.DE's P/E ratio is 40.31. In terms of profitability, GIS.DE's ROE is +0.41%, compared to LLY.DE's ROE of +0.98%. Regarding short-term risk, GIS.DE is more volatile compared to LLY.DE. This indicates potentially higher risk in terms of short-term price fluctuations for GIS.DE.Check LLY.DE's competition here

Stock price comparison of stocks in the Healthcare Sector

Loading...

Frequently Asked Questions